News
TD Cowen Initiates Coverage On Halozyme Therapeutics with Outperform Rating, Announces Price Target of $54
29 Feb 24
News, Price Target, Initiation, Analyst Ratings
JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price Target
21 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
21 Feb 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $50
21 Feb 24
News, Price Target, Analyst Ratings
Halozyme Therapeutics Q4 Adj EPS $0.82 Misses $0.83 Estimate, Sales $230.04M Miss $233.19M Estimate
20 Feb 24
Earnings, News
Earnings Preview: Halozyme Therapeutics
19 Feb 24
Earnings
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
29 Jan 24
Biotech, Equities, Large Cap, News, Health Care, General
Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
19 Jan 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $48 Price Target
19 Jan 24
News, Price Target, Reiteration, Analyst Ratings
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
18 Jan 24
Analyst Color, Biotech, Equities, News, Guidance, Health Care, Price Target, Reiteration, Analyst Ratings, Movers, Trading Ideas, General
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
18 Jan 24
Analyst Ratings
JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price Target
18 Jan 24
News, Price Target, Reiteration, Analyst Ratings
Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Lowers Price Target to $40
18 Jan 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Lowers Price Target to $48
18 Jan 24
News, Price Target, Analyst Ratings
Halozyme Therapeutics Sees FY25 EPS $4.10–$4.50, Revenue $1.04B–$1.115B; FY26 EPS $5.30–$5.80, Revenue $1.265B–$1.365B; FY27 EPS $6.70–$7.30, Revenue $1.515B–$1.64B; FY28 EPS $6.90–$7.50, Revenue $1.565B–$1.690B
17 Jan 24
News, Guidance
Halozyme Therapeutics Releases Investor Presentation: Sees FY23 EPS $2.77-$2.80 Vs $2.74 Est.; Revenue $827M-$832M Vs $835.69M Est.; FY24 EPS $3.55-$3.90 Vs $3.69 Est.; Revenue $915M-$985M Vs $1.1B Est.
17 Jan 24
News, Guidance
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
16 Jan 24
Biotech, Large Cap, Health Care, Markets, General
Roche Receives European Commission Approval Of Tecentriq SC With Halozyme's ENHANZE Representing The EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy For Multiple Cancer Types
16 Jan 24
News
Press releases
Halozyme to Participate in Upcoming Investor Conferences
27 Feb 24
Press Releases
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
20 Feb 24
Earnings, Press Releases
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
16 Feb 24
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
8 Feb 24
Press Releases
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
29 Jan 24
Press Releases
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
18 Jan 24
Press Releases
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
16 Jan 24
Press Releases
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
16 Jan 24
Press Releases
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
12 Jan 24
Earnings, Press Releases